Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ATRS's Cash to Debt is ranked higher than
96% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.75 vs. ATRS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ATRS' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.68
ATRS's Equity to Asset is ranked higher than
65% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ATRS: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
ATRS' s Equity to Asset Range Over the Past 10 Years
Min: -4.09  Med: 0.6 Max: 0.95
Current: 0.68
-4.09
0.95
Interest Coverage No Debt
ATRS's Interest Coverage is ranked higher than
97% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.93 vs. ATRS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ATRS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: -0.11
M-Score: -3.01
WACC vs ROIC
4.16%
-120.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -54.85
ATRS's Operating margin (%) is ranked lower than
82% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. ATRS: -54.85 )
Ranked among companies with meaningful Operating margin (%) only.
ATRS' s Operating margin (%) Range Over the Past 10 Years
Min: -215.47  Med: -105.58 Max: -26.96
Current: -54.85
-215.47
-26.96
Net-margin (%) -54.98
ATRS's Net-margin (%) is ranked lower than
80% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. ATRS: -54.98 )
Ranked among companies with meaningful Net-margin (%) only.
ATRS' s Net-margin (%) Range Over the Past 10 Years
Min: -224.17  Med: -104.33 Max: -26.66
Current: -54.98
-224.17
-26.66
ROE (%) -39.35
ATRS's ROE (%) is ranked lower than
79% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.61 vs. ATRS: -39.35 )
Ranked among companies with meaningful ROE (%) only.
ATRS' s ROE (%) Range Over the Past 10 Years
Min: -280.93  Med: -69.41 Max: -19.42
Current: -39.35
-280.93
-19.42
ROA (%) -30.98
ATRS's ROA (%) is ranked lower than
81% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. ATRS: -30.98 )
Ranked among companies with meaningful ROA (%) only.
ATRS' s ROA (%) Range Over the Past 10 Years
Min: -91.53  Med: -38.32 Max: -15.37
Current: -30.98
-91.53
-15.37
ROC (Joel Greenblatt) (%) -153.21
ATRS's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.27 vs. ATRS: -153.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATRS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2034.35  Med: -942.81 Max: -151.84
Current: -153.21
-2034.35
-151.84
Revenue Growth (3Y)(%) 14.90
ATRS's Revenue Growth (3Y)(%) is ranked higher than
87% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ATRS: 14.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ATRS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.5  Med: 9.9 Max: 93.3
Current: 14.9
-63.5
93.3
EBITDA Growth (3Y)(%) 8.10
ATRS's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. ATRS: 8.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ATRS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.5  Med: -12.3 Max: 80.8
Current: 8.1
-41.5
80.8
EPS Growth (3Y)(%) 11.90
ATRS's EPS Growth (3Y)(%) is ranked higher than
66% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. ATRS: 11.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ATRS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.2  Med: -10.6 Max: 75.4
Current: 11.9
-58.2
75.4
» ATRS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ATRS Guru Trades in Q3 2015

Jim Simons 289,041 sh (+58.00%)
First Eagle Investment 20,000 sh (unchged)
» More
Q4 2015

ATRS Guru Trades in Q4 2015

Paul Tudor Jones 14,685 sh (New)
Chuck Royce 97,284 sh (New)
Jim Simons 1,385,438 sh (+379.32%)
First Eagle Investment 20,000 sh (unchged)
» More
Q1 2016

ATRS Guru Trades in Q1 2016

Chuck Royce 406,900 sh (+318.26%)
Jim Simons 2,231,169 sh (+61.04%)
First Eagle Investment 20,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2016

ATRS Guru Trades in Q2 2016

Jim Simons 2,717,852 sh (+21.81%)
First Eagle Investment 20,000 sh (unchged)
Chuck Royce 406,900 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ATRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:IVTY, AMEX:TRXC, NAS:SIEN, NAS:DSCI, NAS:SSRG, NAS:UTMD, AMEX:BVX, NAS:HBIO, OTCPK:TDMMF, AMEX:CRHM, NAS:BIOL, AMEX:RVP, NAS:HNSN, NAS:LAKE, NAS:LENS, AMEX:MLSS, NAS:EKSO, AMEX:INFU, NAS:PLSE, OTCPK:TSNLF » details
Traded in other countries:MJC.Germany,
Antares Pharma Inc is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies including novel, pressure-assisted injectors.

Antares Pharma Inc was incorporated on February 1979. The Company is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies. It develops & manufactures novel, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. The Company has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It also developed a disposable multi-dose pen injector for use with standard cartridges. The Company developed the Vibex auto injector for its product OTREXUP. The Company has launched OTREXUP injection, subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. The Company is conducting clinical studies of Vibex QS T, for testosterone replacement therapy. It is also developing VIBEX Sumatriptan for the acute treatment of migraines. The Company's development projects include VIBEX epinephrine, an exenatide multi-dose pen, and another undisclosed multi-dose pen. The Company also makes a reusable, needle-free, spring-action injector device known as the Tjet and Zomajet, which is marketed for use with human growth hormone. The Company also has a portfolio of gel-based products inclduing Gelnique for the treatment of overactive bladder. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, Novartis, Mylan, Roxane, Bedford Labs, Hospira, and Accord Healthcare. Any potential products discovered, developed and manufactured by the Company must comply with comprehensive regulation by the FDA in the U.S. and by comparable authorities in other countries.

Ratios

vs
industry
vs
history
P/B 3.60
ATRS's P/B is ranked lower than
51% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.07 vs. ATRS: 3.60 )
Ranked among companies with meaningful P/B only.
ATRS' s P/B Range Over the Past 10 Years
Min: 1.83  Med: 7.84 Max: 86.11
Current: 3.6
1.83
86.11
P/S 4.06
ATRS's P/S is ranked lower than
55% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. ATRS: 4.06 )
Ranked among companies with meaningful P/S only.
ATRS' s P/S Range Over the Past 10 Years
Min: 2.13  Med: 12.07 Max: 32.73
Current: 4.06
2.13
32.73
Current Ratio 2.44
ATRS's Current Ratio is ranked lower than
52% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. ATRS: 2.44 )
Ranked among companies with meaningful Current Ratio only.
ATRS' s Current Ratio Range Over the Past 10 Years
Min: 0.11  Med: 3.38 Max: 17.17
Current: 2.44
0.11
17.17
Quick Ratio 2.13
ATRS's Quick Ratio is ranked higher than
62% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. ATRS: 2.13 )
Ranked among companies with meaningful Quick Ratio only.
ATRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.09  Med: 3.28 Max: 16.5
Current: 2.13
0.09
16.5
Days Inventory 85.78
ATRS's Days Inventory is ranked higher than
73% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.07 vs. ATRS: 85.78 )
Ranked among companies with meaningful Days Inventory only.
ATRS' s Days Inventory Range Over the Past 10 Years
Min: 11.13  Med: 29.5 Max: 200.11
Current: 85.78
11.13
200.11
Days Sales Outstanding 79.21
ATRS's Days Sales Outstanding is ranked lower than
74% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.94 vs. ATRS: 79.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.3  Med: 52.28 Max: 86.08
Current: 79.21
18.3
86.08
Days Payable 156.98
ATRS's Days Payable is ranked higher than
85% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.53 vs. ATRS: 156.98 )
Ranked among companies with meaningful Days Payable only.
ATRS' s Days Payable Range Over the Past 10 Years
Min: 85.36  Med: 158.69 Max: 380
Current: 156.98
85.36
380

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.10
ATRS's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. ATRS: -7.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATRS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -140.2  Med: -16.5 Max: -0.7
Current: -7.1
-140.2
-0.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.14
ATRS's Price/Net Cash is ranked higher than
51% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.00 vs. ATRS: 18.14 )
Ranked among companies with meaningful Price/Net Cash only.
ATRS' s Price/Net Cash Range Over the Past 10 Years
Min: 1.18  Med: 12.27 Max: 135.5
Current: 18.14
1.18
135.5
Price/Net Current Asset Value 5.77
ATRS's Price/Net Current Asset Value is ranked higher than
64% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. ATRS: 5.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATRS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.89  Med: 8.57 Max: 54
Current: 5.77
0.89
54
Price/Tangible Book 3.85
ATRS's Price/Tangible Book is ranked higher than
57% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. ATRS: 3.85 )
Ranked among companies with meaningful Price/Tangible Book only.
ATRS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.62  Med: 7.03 Max: 1000
Current: 3.85
0.62
1000
Price/Median PS Value 0.34
ATRS's Price/Median PS Value is ranked higher than
93% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. ATRS: 0.34 )
Ranked among companies with meaningful Price/Median PS Value only.
ATRS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.08  Med: 0.82 Max: 19.62
Current: 0.34
0.08
19.62
Earnings Yield (Greenblatt) (%) -16.25
ATRS's Earnings Yield (Greenblatt) (%) is ranked lower than
85% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. ATRS: -16.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATRS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -33.02  Med: 0 Max: 0
Current: -16.25
-33.02
0

More Statistics

Revenue (TTM) (Mil) $47.44
EPS (TTM) $ -0.17
Beta0.35
Short Percentage of Float2.49%
52-Week Range $0.67 - 2.03
Shares Outstanding (Mil)155.06

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17
Revenue (Mil $) 55 78
EPS ($) 0.01 0.05
EPS w/o NRI ($) 0.01 0.05
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ATRS

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BioDelivery Sciences International, TheStreet, Antares Pharma Mar 27 2016 
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

More From Other Websites
Have You Heard About This Generic EpiPen Maker? Aug 24 2016
ANTARES PHARMA, INC. Financials Aug 19 2016
ETF’s with exposure to Antares Pharma, Inc. : August 16, 2016 Aug 16 2016
Antares Pharma, Inc. :ATRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 Aug 15 2016
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers Aug 11 2016
Antares Pharma reports 2Q loss Aug 09 2016
Antares Pharma reports 2Q loss Aug 09 2016
Q2 2016 Antares Pharma Inc Earnings Release - Before Market Open Aug 09 2016
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 09 2016
Antares Pharma Reports Second Quarter 2016 Operating and Financial Results Aug 09 2016
Antares Pharma to Report Second Quarter Financial and Operating Results and Host Webcast and... Aug 02 2016
Antares Pharma to Report Second Quarter Financial and Operating Results and Host Webcast and... Aug 02 2016
ETF’s with exposure to Antares Pharma, Inc. : July 26, 2016 Jul 26 2016
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jul 01 2016
Antares Pharma (ATRS) in Focus: Stock Moves 10.2% Higher Jun 28 2016
TEVA and Antares Pharma Announce Launch of Generic Imitrex in the United States Jun 27 2016
Teva and Antares Pharma Announce Launch of Generic Imitrex® in the United States Jun 27 2016
Antares Pharma Announces Settlement of Patent Litigation for Key Alliance Business Product Jun 23 2016
Antares Pharma Announces Settlement of Patent Litigation for Key Alliance Business Product Jun 23 2016
ETF’s with exposure to Antares Pharma, Inc. : June 20, 2016 Jun 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)